Search results
Results From The WOW.Com Content Network
MannKind Corp (NASDAQ: MNKD) is trading significantly lower Monday morning after the company announced the FDA issued a complete response to United Therapeutics regarding the New Drug Application ...
For premium support please call: 800-290-4726 more ways to reach us
Get breaking news and the latest headlines on business, entertainment, politics, world news, tech, sports, videos and much more from AOL. ... USA TODAY 4 hours ago
MannKind Corporation is a biopharmaceutical company focusing on the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and pulmonary arterial hypertension. Based in Danbury, Connecticut, the company was founded in February 1991. MannKind Corporation was named after its founder, Alfred E. Mann.
Let's take a look at MannKind (NAS: MNKD) today, and see why. When considering any stock for your portfolio, don't be swayed by just the positives. Examine its pros and cons, and decide whether ...
MannKind (NAS: MNKD) announced today that it licensed its preclinical BTK (Bruton's tyrosine kinase) program to Tolero Pharmaceuticals but included a take-back option in the deal. MannKind has ...
MannKind (NAS: MNKD) announced breathtaking news this week -- literally. The biotech completed patient recruitment for two phase 3 clinical trials for its insulin inhalant Afrezza. The ...
For premium support please call: 800-290-4726 more ways to reach us